Intra-Cellular Therapies ...
(ITCI) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
83.72
-0.08%
After-hours Jan 03, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | n/a | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
Cost of Revenue | 33.74M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
Pretax Income | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
Selling & General & Admin | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
Other Expenses | n/a | -1.18M | -2.10M | -282.23K | n/a | n/a | -245.84K | -330.70K | -60.70K | -29.75K | n/a | n/a |
Operating Expenses | 590.01M | 492.31M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
Interest Expense | n/a | 7.38M | n/a | n/a | n/a | n/a | n/a | 36.78K | n/a | 7.07K | 612.96K | 193.50K |
Selling & Marketing Expenses | 92.20M | 85.80M | 82.50M | 36.30M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
Income Tax | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
Shares Outstanding (Basic) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
Shares Outstanding (Diluted) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
EPS (Basic) | -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
EPS (Diluted) | -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
EBITDA | -158.85M | -262.97M | -285.15M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |